Tuesday, 21 January 2020

Herbal Medicine Market Global Sales, Revenue, Price and Gross Margin Forecast To 2023

Herbal Medicine Industry report anlayzes Herbal Medicine Market for Category (Herbal Pharmaceuticals, Herbal Functional Foods, Herbal Beauty Products and Herbal Dietary Supplements), by Type of Medicinal Plants (Marrubium Vulgare, Vaccinium Macrocarpon, Echinacea, Curcuma Longa, Camellia Sinensis, Actaea Racemose, Aloe Vera, Zingiber Officinale, Cocos Nucifera, Cinnamomum Spp and Allium Sativum), by Form (Extracts, Powders, Capsules & Tablets and Syrups), by Source (Leaves, Root & Barks, Whole Plants and Fruits), by Distribution Channel and by Region and Forecast till 2023
The Global Herbal Medicine Market value is expected to register a CAGR of 5.88% to reach USD 1,29,689.3 million by 2023.
Herb is a plant or plant part used for its scent, flavor, or therapeutic properties. Herbal medicines are a type of dietary supplements. They are sold as tablets, capsules, powders, teas, extracts, and fresh or dried plants. People use herbal medicines to maintain and improve their health. Many conventional drugs originate from plant sources, and most of the few effective drugs are plant-based. Examples include aspirin (from willow bark), digoxin (from foxglove), quinine (from cinchona bark), and morphine (from the opium poppy). The development of drugs from plants continues, with drug companies engaged in the large-scale pharmacologic screening of herbs.
Key Players
The prominent players in the global herbal medicine market are Arkopharma, Bayer AG, BEOVITA, Hishimo Pharmaceuticals, Schaper & Brümmer, ZeinPharma Germany GmbH, Venus Pharma GmbH, Dasherb Corp, and Arizona Natural Products among other.
Some of the key strategies followed by the players operating in the global herbal medicine market were innovation, product development, acquisition, and expansion.
Market Dynamics
Herbal medicines are used since ancient times for numerous health conditions. It is the oldest and most extensively used system of medicine in the world today. There are various kinds of herbal medicines and supplements used across the world. According to the National Center for Biotechnology Information, 2015, the World Health Organization (WTO), reported that around 70% to 80% of people globally rely on herbal sources for their treatment. Also, according to the American Botanical Council, September 2017, it was reported that in 2016, the sale of herbal supplements increased by 7.7% in the US. It was also estimated that consumers spending on herbal supplements increased to USD 7.452 billion in 2016. Thus, the increase in the demand for herbal products for healthcare purposes is likely to enhance this market during the forecast period.

Segmentation
The global herbal medicine Market, by category, is segmented into herbal pharmaceuticals, herbal dietary supplements, herbal functional foods, and herbal beauty products. The herbal pharmaceutical segment led the herbal medicine market with USD 50,972.4 million in 2017. The herbal pharmaceutical segment is growing owing to the increasing research and development on various herbs to find their medicinal properties, growing demand for natural medicines having fewer side-effects, and rising prevalence of chronic diseases such as diabetes, arthritis, cancer, sleep disorders, and digestive problems.
Marrubium vulgare segment is the fastest-growing segment of the market at CAGR of 6.45% during the forecast period. Marrubium vulgare also known as white horehound is a largely cultivated plant, and its above-ground parts are used for medicinal use. The upper part of the plant is used in powder, liquid extract, or juice form for medicinal purposes. Marrubium vulgare is largely used for digestion problems which include indigestion, loss of appetite, gas, bloating, diarrhea, constipation, and gallbladder complaints. It is also used for the treatment of breathing problems
The global herbal medicine Market, by form, is segmented into extracts, powders, capsules and tablets, syrups, and others. The extracts segment accounted for the largest market share of 36.95% in 2017.
The global herbal medicine Market, by source, is segmented into leaves, fruit, roots, and barks whole plant, and others (combinations of various plant parts). On the basis of source, the leaves segment is expected to lead the global herbal medicine market. The leaves segment held a share of USD 51,495.2 million in 2017.
The global herbal medicine Market, by distribution channel, is segmented into hospital and retail pharmacies, e-commerce, and others. The hospital & retail pharmacies segment accounted for the largest market share of 55.82% in 2017. The growing prevalence of cancer and infectious diseases across the globe, improving healthcare infrastructure, and skilled professionals are driving the growth of hospital and retail pharmacies in the herbal medicine market.
Regional Analysis
Europe is expected to account for the largest market share owing to extensive R&D for herbal medicine, increasing funding for research on medicinal plants, and growing preference for herbal drugs globally. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead market growth during the forecast period. The increasing prevalence of chronic diseases and rising government support facilitate market growth within the region.
Americas accounts for the second largest share in the global herbal medicine market. It accounted for a considerable market share of 16.2% as of 2017. The use of herbal medicines is also growing in the US after conducting the first national study of alternative and complementary medicines used by Eisenberg et al. According to the National Center for Biotechnology Information 2017, it was reported that herbal supplements were majorly used for conditions such as cancer (43.1%), stroke (48.7%), and arthritis (43%) in the US. Such a high demand and preference for herbal products is likely to boost the market growth during the forecast period.
Asia-Pacific is expected to register a CAGR of 5.99% during the forecast period owing to the adoption of traditional medicines by pharmaceutical companies, researchers, and policymakers. On the other hand, the Middle East and Africa are expected to observe a slow growth due to less awareness and in-depth knowledge about herbal drugs in this region.
Posted by at No comments:

Age-Related Macular Degeneration Market Global Sales, Revenue, Price and Gross Margin Forecast To 2023

Market Research Future presents Age-Related Macular Degeneration (AMD) Market Research Report Analysis By Type (Wet AMD & Dry AMD), by Stages (Intermediate AMD, Early AMD, & Late AMD), by Age Group (Above 75, Above 60, & Above 40), by Diagnosis & Treatment, and End-User Forecast Till 2023
Market scenario:
This MRFR study offers a vivid view of the global age-related macular degeneration AMD market. The study includes an in-depth analysis of macro and micro-economic factors likely to influence the market during the forecast period. It further summarizes the key market opportunities and trends.
The Global Age-Related Macular Degeneration Market insights by MRFR assert, the market expected to register a CAGR of 7.80% to reach USD 11,186.8 Million by 2023. Age-related macular degeneration (AMD) is a chronic irreversible medical condition that results in central vision loss because of damage to the central area of the retina (macula). This condition is majorly categorized as dry age-related macular degeneration and wet age-related macular degeneration.
Growing geriatric population and increasing prevalence of age-related macular degeneration, several branded drugs going off-patent are expected to enhance market growth. However, factors such as high cost associated with AMD, stringent FDA regulations may restrain the market growth during the forecast period.
Key Players
The prominent players in the global age-related macular degeneration market are Novartis AG, Pfizer Inc, F. Hoffmann-La Roche AG, Acucela Inc., Ophthotech Corporation, GlaxoSmithKline PLC, Bayer AG, Rxi Pharmaceuticals, Inc., Regeneron Pharmaceutical Inc., Alimera Sciences Inc., Santen Pharmaceuticals Co., ALLERGAN, and Bausch & Lomb Incorporate.
Market Dynamics
The global age-related macular degeneration market has been primarily driven by growing geriatric population and increasing prevalence of age-related macular degeneration, several branded drugs going off patent. For instance, according to the 2017 statistics suggested by the United Nations, it was estimated that 962 million people aged 60 or above comprise 13% of the global population. Factors such as high cost associated with AMD, stringent FDA regulations may restrain the market growth during the forecast period.
Segmentation
The global age-related macular degeneration market has been segmented into type, stages, age group, treatment, and route of administration. Based on type, the market has been classified as wet age-related macular degeneration (wet AMD) and dry age-related macular degeneration (dry AMD). Dry age-related macular degeneration (dry AMD) held a market share of 2,092.6 USD million in 2017. Based on stages the market has been divided into intermediate-stage age-related macular degeneration, early-stage age-related macular degeneration, late-stage age-related macular degeneration. On the basis of age group, the market has been bifurcated into above 75 years, above 60 years, and 40 years. Based on treatment, the market has been divided into treatment and Diagnosis. Based on the route of administration, the market has been classified as an intravitreal route of administration and intravenous route of administration. Based on the end user, the market has been segmented into hospital & clinics, diagnostic centers, and academic research institutes.
Regional Analysis
The global age-related macular degeneration market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas dominate the global age-related macular degeneration market is owing to the rising ophthalmological disorders and increasing aging population. Nearly 7.3 million people are at significant risk of vision loss due to AMD.
Europe holds the second largest market share due to increasing older population and rising patient population. Additionally, improving government initiatives and increasing healthcare frame along with growing demand for technologically innovative treatment is driving the growth of age-related macular degeneration market in Europe
Asia-Pacific is estimated to be the fastest-growing region in the global age-related macular degeneration as it is developing at a very rapid pace and has shown the emergence of many players. Moreover, rising prevalence of eye disorders, increasing healthcare spending, and multinational companies moving towards the developing nations and setting operational set-ups are likely to drive the growth of the market. Japan held a market share of 23.2% in 2017.
The Middle East & Africa are expected to witness restricted growth due to limited access and healthcare affordability among the population. In the Middle East, the growth of the market is driven by increasing healthcare infrastructure and healthcare expenditure.
Posted by at No comments:
Labels:

Genetic Testing Market Global Sales, Revenue, Price and Gross Margin Forecast To 2024

Genetic Testing Market is expected to grow at CAGR of 11.50% to reach USD 22834.19 million till 2024, revealed by Market Research Future (MRFR) with Global Genetic Testing Market Analysis by by Type, Method, by Application, and Regions - Americas, Europe, Asia-Pacific and Middle East & Africa and Forecast till 2024
Key Players
The prominent players in the global genetic testing market are Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Illumina Inc. (US), Myriad Genetics, Inc. (US), PerkinElmer Inc. (US), QIAGEN N. V.  (Germany), Quest Diagnostics Incorporated (US), Eurofins Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Blueprint Genetics (Finland), BGI Genomics (China), and Thermo Fisher Scientific Inc. (US).
Market Insights:
Genetic testing is also known as DNA testing. Genetic tests involve a set of lab tests for the study of the genetic makeup of patients and identify any gene mutations and alterations in the healthy structure of DNA leading to the development of genetic disorders.
Some of the protuberant drivers supporting the growth of the global genetic testing market are identified as raising awareness about the benefits of genetic testing and the rising prevalence of genetic disorders.
Additionally, the role of genetic tests in forensic investigations and change in the trend of the genetic testing industry from service-driven to product-driven industry are expected to drive the global genetic testing market in the coming years.
Genetic testing offers a lot of benefits such as the chance for taking preventive measures to avoid potential diseases and lead a healthy life, knowledge about genetic alterations in the fetus that may lead to abnormal growth, and aids forensic investigations, among others. Due to the great benefits provided by these tests, people are getting more aware of them. This phenomenon intrigues people to go for tests to understand their genetic structure and possible disorders they may have to go through. The growing awareness has gathered a lot of audience for the genetic testing market and has also positively impacted the growth of this market.
Moreover, there has been tremendous growth in the prevalence of genetic disorders which may be due to various reasons such as geographical and environmental changes, change in food habits, pollution, and exposure to harmful radiations or chemicals. Genetic tests are also used to analyze family relations such as father, mother, half-brother, half-sister, and others. Forensic science and genetic testing have aided law and order to a great extent. With an increasing number of companies entering into this segment, the overall market for genetic tests has increased and expected to grow fast in the near future.
Some of the key strategies followed by the players operating in the global genetic testing market were innovation, product development, acquisition, and expansion.
  • In April 2017, Myriad Genetics, Inc. signed an agreement with Clovis Oncology for the use of its FDA-Approved BRACAnalysis CDx Test to identify patients with germline BRCA Mutations for the Rubraca (rucaparib) treatment.
  • In January 2017, Bio-Rad Laboratories, Inc. announced the launch of the Single Cell Sequencing Solution in collaboration with Illumina Inc.
  • In August 2016, Abbott Laboratories launched Alinity, a family of next-generation system.
Segmentation                                                                                                                                        
Global genetic testing Market, by type, segmented into prescribed genetic testing and direct to consumer genetic testing. Prescribed genetic testing is the leading segment, which is growing at the highest CAGR to reach USD 21653.91 million by the end of 2024. Its large market share is majorly attributed to the widespread availability and service providers of various genetic tests and less availability of direct to consumer tests in all parts of the world.
Based on method, the genetic testing market is segmented into molecular genetic tests/ DNA tests, chromosomal genetic tests, and biochemical genetic tests. The molecular genetic test/DNA tests account for major share with 11.78% CAGR during the forecast period. Molecular testing helps to determine the sequence in DNA or RNA related to a particular disease.
The genetic testing market, by application, is segmented into reproductive health, cancer screening, ancestry, predictive and pre-symptomatic testing, and others. The reproductive health segment accounted for the largest market share of 33.61% in 2018.
Regional Analysis         
The Americas accounted for the largest market share of the global genetic testing market, by region in 2018. This large share is majorly due to high awareness about genetic testing, high disposable income of the population, and implementation of newborn screening in the majority of the hospitals in the region. In 2015, approximately 12 million Americans suffered from genetic diseases which are approximately 1 in 20 people.
Europe accounted for the second largest market share. Technological advances, well-developed health care sector, and governmental support for the research and development of different tests and devices have provided fuel for the growth of the market. Germany commands the largest market share in the Europe genetic testing market.
Asia-Pacific is the fastest growing region for genetic testing. The presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market drive the growth of the Asia-Pacific genetic testing market. The Middle East & Africa accounted for the 8.8% market share in 2018.
Posted by at No comments:

Global Vocal Cord Paralysis Market Trends, Demand and Forecast to 2023

Global Vocal Cord Paralysis Market: Information by Type (Unilateral and Bilateral), Treatment (Voice Therapy and Surgery) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2023
Market Dynamics
Vocal Cord Paralysis Market is driven by rising prevalence of causing factors of vocal cord paralysis and technological advancements. For instance, according to the American Cancer Society, the estimated number of new cancer cases involving larynx was 13,360 in the US for the year 2017. Moreover, increasing healthcare expenditure has fueled the growth of the market. On the other hand, the high cost of treatment is anticipated to hamper the market growth.
Market Scenario
The Global Vocal Cord Paralysis Market Growth is expected to register a CAGR of 3.8%and is anticipated to reach USD 2,920.2 Million by 2023. Vocal cord paralysis is caused by the disruption of nerve impulses to the muscles of the larynx or voice box. It may be caused by injury to the head, neck, or chest; lung or thyroid cancer; tumors of the neck or chest; or infection. The nerves controlling the vocal cords are long and can be vulnerable to injury in parts of the body, not usually associated with the vocal cords.
The increasing prevalence of causing factors of vocal cord paralysis, technological advancements, and growing healthcare expenditure are the major drivers propelling market growth. However, the high cost associated with the treatment is expected to constrain the growth of the market.
Competitive Landscape
Key players in the vocal cord paralysis market include Cytophil, Inc. (U.S.), Teleflex Incorporated (U.S.), Medtronic Plc (U.S.), Olympus Corporation (Japan), Stryker Corporation (U.S.), FUJIFILM Holdings Corporation (Japan), LifeCell Corporation (U.S.), Therapy Solutions Inc. (U.S.), KARL STORZ GmbH & Co. KG (Germany), and Smiths Group Plc (U.K.).
The report offers a comprehensive analysis on the profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, expansion techniques, and latest R&D initiatives are discussed in minute detail.
Segmentation
By type, the market is divided into unilateral and bilateral. Treatment options in the vocal cord paralysis market voice therapy and surgery. The surgery treatment segment is further divided into structural implants, tracheotomy, bulk injection (phonosurgery), and vocal cord repositioning. The segments covered in the vocal cord paralysis market report are analyzed with respect to four regions namely – Americas, Middle East & Africa (MEA), Asia Pacific (APAC), and Europe. The report discusses in detail the various players residing in these regions and their respective strategies to climb up the market standings.
Regional Analysis
By region, the global vocal cord paralysis market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).
The Americas accounted for the largest share of 35.4% share of the global market in 2017 and is due to reach USD 1,007.5 Mn in 2023 at a CAGR of 3.4% by the end of the forecast period. Robust healthcare sector, technological superiority, and rising expenditure ion healthcare sector drive the market in the Americas. In addition, the region is highly aware of the medical condition which is acts a plus for the growth of the market.
Europe is a prominent market for vocal cord paralysis and is likely to scale valuation of USD 958.1 Mn at a CAGR of 4% by the end of the forecast period. Similar factors spur the Europe market as the Americas. Also, favorable reimbursement policies and high government support create a conducive environment for the growth of the Europe vocal cord paralysis market.
APAC vocal cord paralysis market is likely to exhibit rapid growth over the forecast period and emerge as the fastest growing market over the forecast period. The increasing prevalence of laryngeal cancer, availability of affordable treatment options and high expenditure on healthcare drive the market in APAC. The APAC market is expected to capture a CAGR of 4.11% over the forecast period.
The MEA market for vocal cord is expected to hold the least share of the market and expand at a CAGR of 3.90% over the forecast period.
Posted by at No comments:
Labels:

Huge Growth and Opportunities in Global ICP-OES Spectrometer Market Till 2025

Global ICP-OES Spectrometer Market Research Report: Information by Spectrometer Type (Sequential, Simultaneous), Application (Nanotechnology, Drug Discovery, Environmental Testing, Food & Agriculture, Others), End User (Pharmaceutical and Biotechnology Companies, Research and Academic Institutes, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025
ICP-OES Spectrometer Market Highlights:
ICP-OES Spectrometer is an analytical instrument that is used for the detection of chemical elements. It uses the technique of inductively coupled plasma optical emission spectroscopy (ICP-OES) for carrying out its analysis procedure. Certain factors that propel the growth of the ICP-OES spectrometer market include increasing R&D expenditure for the development of better analytical systems and growing technological advancements.
However, the high cost of instruments and requirement of large capital investment for setting up instrument manufacturing plants is hindering the growth of the global ICP-OES spectrometer market in the forecast period.
The Global ICP-OES Spectrometer Market size is expected to register a CAGR of 7.2% during the forecast period of 2019 to 2025 with a market value of USD 521.4 million in 2018.
Currently, the global ICP-OES spectrometer market is dominated by several players. The major players in this market are involved in strategic acquisitions and product launches to expand their product portfolios. For instance, in March 2016, GBC Scientific Equipment launched the OptiMass 9600, which uses the ICP-OES spectrometer technology.
Key Players:
Some of the key players in the global ICP-OES spectrometer market are PerkinElmer Inc. (US), Shimadzu Corporation (Japan), GBC Scientific Equipment (Australia), Thermo Fisher Scientific (US), Agilent Technologies, Inc. (US), SPECTRO Analytical Instruments GmbH (Germany), Teledyne Leeman Labs (US), Analytik Jena AG (Germany), Horiba (Japan), Skyray Instrument Inc. (US), Beijing Huake Tiancheng Technology Co., Ltd (China), FPI (China), Hitachi High-Technologies Corporation (Japan), Merck KGaA (Germany), and others.
Segmentation:
The global ICP-OES spectrometer market has been segmented based on spectrometer type, application, and end user.
The market, based on spectrometer type, has been bifurcated into sequential and simultaneous. The sequential spectrometer market is expected to hold a major share in the market owing to its wider availability in the market. The simultaneous spectrometer segment is anticipated to be the fastest growing due to its rising adoption rate.
The market, by application, has been divided into nanotechnology, drug discovery, environmental testing, food & agriculture, and others. The drug discovery segment is expected to hold a major share owing to a large number of applications of ICP-OES spectrometer in this field. The environmental testing segment is expected to be the fastest growing due to an increasing number of research activities for using ICP-OES spectrometer for environmental testing purpose.
The market, by end user, has been classified as pharmaceutical & biotechnology companies, research & academic institutes, and others. Pharmaceutical & biotechnology companies are anticipated to hold a major share in the market. This is due to the increasing number of applications of ICP-OES spectrometer in the pharmaceutical industry. The research & academic institutes segment is expected to become the fastest growing market due to the increasing research activities.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The ICP-OES spectrometer market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European ICP-OES spectrometer market has been sub-divided Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The ICP-OES spectrometer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The ICP-OES spectrometer market in the Middle East & Africa has been divided into the Middle East and Africa.
Regional Analysis:
The market in the Americas is expected to dominate the global ICP-OES spectrometer market due to the growing expenditure on R&D to develop new technologies and the high adoption of new technology in the region. Moreover, the presence of major companies such as PerkinElmer Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, etc. in North America is also expected to fuel the market growth in the region.
The market in Europe showed a substantial amount of growth. The market growth in this region can be attributed to the presence of a well-established healthcare system and increasing adoption of ICP-OES spectrometer for research purposes.
The market in Asia-Pacific is projected to have the fastest growth rate during the forecast period owing to the rapid growth of the pharmaceutical industry in countries such as China, India, and Japan.
The market in the Middle East & Africa is anticipated to account for the least share of the global market due to low disposable income in the region. Moreover, the presence of major companies in the Middle East and African market is also limited, which is projected to curb the growth of the market in the future.
Browse More Healthcare Reports @
Posted by at No comments:
Labels:

Laboratory Informatics Market Global Segmentation and Major key Players Analysis 2024

Global Laboratory Informatics Market Research Report: Information by Product (Laboratory Information Management Systems (Broad-Based LIMS, Industry-Specific LIMS), Chromatography Data Systems (CDS), Electronic Lab Notebooks (ELN), Electronic Data Capture (EDC) & Clinical Data Management Systems (CDMS), Laboratory Execution Systems (LES), Enterprise Content Management (ECM) and Scientific Data Management Systems (SDMS)), Component (Software and Services), Deployment Model (On-Premise Models, Cloud-Based Models, Remotely Hosted Models), End User (Life Sciences Companies, CROs, Environmental Testing Laboratories and others) and Region - Global Forecast till 2024
Laboratory Informatics Market Highlights:
The global laboratory informatics market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 2422 million in 2018 and is projected to register a CAGR of 7.2% over the forecast period.
The increasing participation of key players is one of the key factors driving the market, says MRFR’s Laboratory Informatics market insights. In 2018, Abbott Laboratories announced the launch of the STARLIMS Quality Manufacturing Solution QM 11.1 to support laboratory productivity and efficiency across diverse sectors of the global manufacturing industry.
Various other factors such as the increase in adoption of cloud-based platforms by CROs, increasing preference towards personalized medicine, untapped emerging markets, rise in regulatory approvals, and rising R&D in the field of medicine are also expected to propel the growth of the market.
However, high maintenance and service costs can hamper market growth over the forecast period.
Key Players:
Some of the key players in the global laboratory informatics market are Agilent Technologies, Inc., Abbott Laboratories, Accelerated Technology Laboratories, Cerner Corporation, Dassault Systèmes, IDBS, KineMatik, Lablynx, Inc., Labvantage Solutions, Inc., Autoscribe Limited, Labware, Labworks LLC, McKesson Corporation, Thermo Fisher Scientific Inc., Perkinelmer Inc., Waters, and others.
Segmentation:
The global laboratory informatics market is segmented based on product, component, deployment model, end user, and region.
The global market for laboratory informatics, by product, is segmented into Laboratory Information Management Systems (LIMS), Chromatography Data Systems (CDS), Electronic Lab Notebooks (ELN), Electronic Data Capture (EDC) & Clinical Data Management Systems (CDMS), Laboratory Execution Systems (LES), Enterprise Content Management (ECM), and Scientific Data Management Systems (SDMS). The Laboratory Information Management Systems (LIMS) segment is further classified as broad-based LIMS and industry-specific LIMS.
Based on component, the market is segmented into software and services.
Based on the deployment model, the market is segmented into on-premise models, cloud-based models, and remotely hosted models.
Based on end user, the market is segmented into life sciences companies, CROs, environmental testing laboratories, and others.
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.
The laboratory informatics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European laboratory informatics market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The laboratory informatics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The laboratory informatics market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Analysis:
The Americas dominated the global market for laboratory clinical informatics owing to the escalating healthcare cost coupled with the rising pressure to bend the cost curve resulted in increased regional adoption of laboratory information management systems. According to the Organization for Economic Co-Operation and Development, in 2018, Americans spent USD 3.65 trillion on healthcare. It is also stated that the level of spending is by far the highest in the developed world.
In 2018, it was estimated that Europe stood second in the global laboratory informatics market. Technological advancements, along with the availability of funding opportunities in research and innovation, will support the growth of healthcare laboratory informatics. Germany commanded the largest share in the European market for medical laboratory informatics due to growing automation of laboratory systems.
Asia-Pacific (APAC) is expected to represent the phenomenal growth in medical informatics throughout the forecast period due to rising participation of market players and increasing healthcare funding. In 2018, Sysmex Corporation, Japan-based company, launched a new network solution Caresphere. The solution is designed to provide new value through the intelligent use of information by people involved in testing and healthcare.
On the other hand, the Middle East and Africa held the least share in the global Laboratory Informatics market due to the low economic development, especially within the African region.
Posted by at No comments:
Labels:

CBD Market Analysis Revealing Key Drivers, Growth Trends and Competitive Assessment through 2026

CBD (Cannabidiol) Market: Information by Form (Solid and Liquid), Route of Administration (Tincture, Capsules, Inhalation (Smoke or Vapor) , Aerosol Spray), Product (Food Grade and Therapeutic Grade), Application (Neurogenerative Disorder, Fibromyalgia, Diabetes , Protein Bars , Energy Drinks), End User (Food & Beverage, Healthcare), Source (Organic Inorganic) and Region (North America, Europe, Asia Pacific, ROW) - Global Forecast till 2026
CBD Market Overview
The Global CBD Market is expected to register a CAGR of 125.58% to reach USD 22,07,162.54 Million by 2026.
Cannabidiol (CBD) is a safe, non-addictive substance found in the cannabis plant. CBD is the second-most abundant cannabinoid found in cannabis after tetrahydrocannabinol (THC). CBD has significant therapeutic benefits such as anti-inflammatory, analgesic, anti-anxiety, and seizure-suppressant properties. According to a survey by the National Center for Biotechnology Information (NCBI) conducted between 2017 and 2018, about 62% of the population used CBD to treat a medical condition.
The growing research & development and financial support by various private and government organizations for cannabinoid research, rising occurrence of chronic diseases and related complications, and legalization of CBD in various regions are expected to have a positive impact on the global cannabidiol (CBD) market. However, adverse effects associated with cannabis and stringent government policies are anticipated to restrain the growth of the global CBD market.
CBD Market Dynamics
Growing research and development activities and financial support by various private and government organizations for cannabinoid research- There are many private and government organizations supporting the research and development for cannabinoids for medical purposes. Cannabis has numerous medicinal properties by which it can cure various diseases. According to the National Institute of Drug Abuse, May 2018 publication, in 2017, the National Institute of Health (NIH) supported 330 projects and spent USD 140 million on cannabinoid research and development. During this investment, USD 36 million was spent on 70 projects to examine the therapeutic properties of cannabis, and USD 15 million was spent on 26 projects centered on cannabinoid (CBD). Even in 2016, NIH spent USD 21 million studying therapeutic properties of cannabinoids. Singapore, known for the world's most stringent drug laws, is also funding research projects on medical treatments containing synthetically derived compounds of the cannabis plant. In 2017, the government-run National Research Foundation launched a program to research the therapeutic potential of cannabinoids.
CBD Market Regional Analysis
The Americas dominate the global CBD market, owing to the increasing consumption of cannabis-based products. According to the World Health Organization (WHO), the consumption of marijuana has an annual prevalence rate of nearly 2.5% of the global population, i.e., approximately 147 million individuals. It is also reported that approximately 22.2 million Americans of 12 years of age and older use cannabis and related products for various reasons.
Europe holds the second largest market share due to the rising awareness about clinical applications of cannabis. CBD is legal and can be openly marketed in certain European countries, for instance, the Ministry of Agriculture, Food and Forestry, and the Bulgarian Food Safety Agency issued the ‘free certificate of sale’ for the CBD products. Thus, such approvals and consideration by the regulatory agencies in Europe are driving the CBD market growth in the region. In spite of the approvals and considerations, there are positive restrictions associated with the use of the products. For instance, in 2013, medical cannabis was legalized in the Czech Republic, but it was limited to 180 grams of dry matter per month. In Europe, marijuana and cannabis laws differ from country to country. Previously, Germany was importing medical cannabis from other countries, but in 2017, Germany passed a law to expand access to medical cannabis and to allow domestic production. Increasing participation of various companies such as Medical Marijuana Inc., as a scope of development, announced the formation of Canipa Holdings in Romania, European Union. The effect of such initiatives by the companies is facilitating the growth of the CBD market in the European region.
The Asia-Pacific region is classified into CBD Market China, CBD Market India, CBD Market Japan, and Rest of Asia-Pacific. It holds the third largest position in the CBD market. Recently, China has legalized the cultivation of CBD (Hemp) and extraction for the derived product. The products are exported and not sold in China. Yunnan provincial government and Public Security Bureau approved the first industrial hemp plant extraction factory in China. It is the largest country in terms of area, population, businesses, and others. The entry of Chinese companies in the CBD market has created a great potential for expansion and growth. In Asia-Pacific, cannabis-based products are completely unacceptable. But due to the increasing cases of epilepsy, cannabis-based products are prescribed by some physicians. For instance, a recent Australian nationwide survey of 976 people with epilepsy indicated that 13% of the parents were using illicit cannabis extracts to manage their child’s seizures. Australia mainly focuses on the medical use of cannabis products. Australian regulatory agencies are operating on providing a guideline for the use of the CBD products. This is expected to help in the growth of the CBD market in Australia.
The Middle East and Africa is expected to witness a restricted growth due to stringent government policies, adverse effects associated with cannabis, and the illegal use of marijuana. In the Middle East, few of the Arab countries are imposing trick laws over the use and handling of cannabis-related products. Thus, the CBD market in these regions has limited scope for growth during the forecast period.
Segmentation
On the basis of form, the global cannabidiol market is segmented into solid and liquid.
In the solid form of CBD, the report covers CBD crystals, CBD wax, capsule/softgel, hash, and others. The liquid form of CBD includes CBD oil, tincture, cream, e-liquid, and others.
CBD crystals are a pure form of CBD isolates. CBD crystals are produced by heating CBD rich extract and then continuous cooling and separating it. CBD crystals are generally used to manufacture CBD infused edibles and creams. CBD wax is solidified or crystalized full spectrum form of CBD. CBD wax is a highly concentrated form of CBD and especially used for pain relief. CBD capsules are similar in comparison to capsules as they are surrounded by an outer shell, usually gelatin. CBD soft gelatin capsule is a translucent golden shade standard capsule that is filled with hemp oil and sometimes olive oil as filler.
CBD oil is one of the most popular and widely available forms of CBD. It is specifically used for medical purposes as it provides fast and effective results. There are a wide variety of flavors of full spectrum CBD oils available in the market. CBD tinctures are made from high strains of hemp, with 60-70% of alcohol. CBD tinctures are primarily used to relieve anxiety and ease the pain. CBD infused e-liquid are used as a fluid in electronic cigarettes and vaporizers.
CBD Market Key Players
The prominent players in the global CBD market are Aphria Inc., Folium Biosciences, Freedom Leaf, Inc, Green Roads of Florida, LLC, CBD Health Solutions, LLC, ENDOCA, Isodiol International Inc, CV Sciences, Inc, Medical Marijuana, Inc., Canopy Growth Corporation, Elixinol Global Limited.
The players operating in the global CBD market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
Posted by at No comments:
Subscribe to: Posts (Atom)